Neuropeptide research
DSIP Dosage, Protocol & Research Guide
- MW 848.8 g/mol
- CAS 62568-57-4
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- 62568-57-4
- Molecular weight
- 848.8 g/mol
- Formula
- Not yet recorded
- Sequence
- WAGGDASGE
- Aliases
- Delta sleep-inducing peptide, Emideltide, Delta-Sleep Peptide
- Vial sizes (mg)
- 5, 10
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- FDA safety-risk page (current as of 04/22/2026), list of bulk drug substances nominated but withdrawn: FDA has not identified safety-related information regarding emideltide (DSIP) for the proposed route of administration.[1] Regulator or expert-panel statement
- FDA safety-risk page (current as of 04/22/2026) states compounded drugs containing emideltide (DSIP) may pose risk for immunogenicity for certain routes of administration.[1] Regulator or expert-panel statement
Regulatory status
Listed in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (current 04/22/2026): emideltide (DSIP); no safety information identified. Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
Double-blind matched-pairs study in 16 chronic insomnia patients (Neuropsychobiology 1992)[2]
Double-blind matched-pairs study in 16 chronic insomnia patients (Neuropsychobiology 1992): DSIP 25 nmol/kg body weight or glucose placebo intravenously in the afternoon before nights 3, 4 and 5
Double-blind crossover study in insomniac patients (Int J Clin Pharmacol Res 1987)[3]
Double-blind crossover study in insomniac patients (Int J Clin Pharmacol Res 1987): DSIP 25 nmol/kg or placebo intravenously during four nights
Sleep-laboratory study in 18 chronic insomniacs (Eur Neurol 1986)[4]
Sleep-laboratory study in 18 chronic insomniacs (Eur Neurol 1986): DSIP 6 x 30 nmol/kg body weight intravenously over one week, with a one-week follow-up
Compare vial sizes
| Size | Price | Doses available from the vial Calculated | Cost per dose Calculated |
|---|---|---|---|
| 5 mg | $24.99 | — | — |
Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.
Calculated from a default of 2 mL water (adjustable).
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.
Frequently asked questions
What is the regulatory status of DSIP?
Listed in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (current 04/22/2026): emideltide (DSIP); no safety information identified. Checked 2026-10-20.
Compound facts
What is the molecular weight of DSIP?
What is the CAS number of DSIP?
How is DSIP stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- fda.gov Regulator or expert-panel statement
- Double-blind matched-pairs study in 16 chronic insomnia patients (Neuropsychobiology 1992) pubmed.ncbi.nlm.nih.gov Human trial
- Double-blind crossover study in insomniac patients (Int J Clin Pharmacol Res 1987) pubmed.ncbi.nlm.nih.gov Human trial
- Sleep-laboratory study in 18 chronic insomniacs (Eur Neurol 1986) pubmed.ncbi.nlm.nih.gov Human trial
Vial sizes and protocols
5 mgPartner size
Available from Pepcore
Supplied as research material for laboratory use only.
- Shop at PepcoreCoupon code
LAUNCH20
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.